ARTICLE | Clinical News
Olokizumab: Development discontinued
November 5, 2012 8:00 AM UTC
UCB disclosed in its financial results for the first 9 months of 2012 that it will discontinue internal development for olokizumab because data "do not suggest sufficient differentiation potential" vs...